Hengrui subcutaneously injected PD-1 into the clinic

On December 8, according to the CDE clinical trial registration platform, Hengrui Medicine SHR-1901 launched the first clinical trial

The Insight database shows that SHR-1901 was first declared for clinical use in June of this year and was approved for clinical use in August

Compared with injections, subcutaneous injection preparations have unique advantages in compliance, fast and convenient administration, and can shorten the administration time from several hours to 3 to 5 minutes, or even in seconds

Roche has also done a patient preference trial PrefHER in the development of trastuzumab subcutaneous formulations.

Hengrui’s Karelizumab is still the leading product among domestic PD-1 monoclonal antibodies in terms of sales.

At present, no other domestic company has pushed PD-1 subcutaneous injection into clinical practice

Pfizer's latest tumor pipeline

From: Pfizer Q3 pipeline update PPT

Sasanlimab has now released Phase 1 clinical data

From: Insight Clinical Results Library (http://db.

As of November 1, 2019, among 106 enrolled patients (NSCLC=68, UC=38), the median duration of treatment was 113.

Prior to the development of Sasanlimab, Pfizer also had a PD-L1 monoclonal antibody (avelumab), which was cooperating with Merck, which was approved by the FDA for marketing in 2017 under the trade name Bavencio®

Note: The original text has been deleted